| Price | 11.05p on 03-12-2025 at 10:23:10 |
|---|---|
| Change | -0.15p -1.34% |
| Buy | 11.40p |
| Sell | 10.70p |
| Last Trade: | Sell 25,825.00 at 11.022p |
| Day's Volume: | 11,050,927 |
| Last Close: | 11.20p |
| Open: | 11.40p |
| ISIN: | GB00BYV81293 |
| Day's Range | 11.05p - 11.925p |
| 52wk Range: | 2.20p - 12.45p |
| Market Capitalisation: | £117.33m |
| VWAP: | 11.70032p |
| Shares in Issue: | 1.06b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Shield Thera (STX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 25,825 | 11.022p | Ordinary |
10:21:05 - 03-Dec-25 |
| Sell* | 150,000 | 11.1999p | Ordinary |
10:18:02 - 03-Dec-25 |
| Buy* | 877 | 11.40p | SI Trade |
10:17:13 - 03-Dec-25 |
| Buy* | 8 | 11.40p | SI Trade |
10:17:13 - 03-Dec-25 |
| Buy* | 438 | 11.40p | SI Trade |
10:17:13 - 03-Dec-25 |
| Buy* | 473 | 11.40p | SI Trade |
10:17:13 - 03-Dec-25 |
| Sell* | 40,000 | 11.15p | Ordinary |
10:15:05 - 03-Dec-25 |
| Buy* | 22,500 | 11.22p | Ordinary |
10:14:31 - 03-Dec-25 |
| Buy* | 1,000 | 11.40p | Ordinary |
10:03:43 - 03-Dec-25 |
| Buy* | 20,000 | 11.22p | Ordinary |
10:02:32 - 03-Dec-25 |
Shield Thera (STX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Nov 2025 7:03 am | RNS | Initiation of a Phase II Clinical Trial in Japan |
| 11th Nov 2025 7:00 am | RNS | ACCRUFeR Pediatric PK Results to be Presented |
| 7th Nov 2025 7:03 am | RNS | ACCRUFeR receives Authorisation by Korean Ministry |
| 23rd Oct 2025 7:00 am | RNS | Q3 2025 Trading Update |
| 14th Oct 2025 3:01 pm | RNS | Grant of Share Options to Chief Executive Officer |
| 1st Oct 2025 8:00 am | RNS | Total Voting Rights |
| 1st Oct 2025 7:02 am | RNS | Positive efficacy and tolerance in pediatric trial |
| 15th Sep 2025 7:00 am | RNS | £1.5 million placing supporting growth of ACCRUFeR |
| 4th Sep 2025 7:03 am | RNS | ACCRUFeR® assigned Priority Review in US by FDA |
| 3rd Sep 2025 2:17 pm | RNS | Interim results for the six months ended 30 Jun 25 |
